Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) – Equities researchers at Zacks Small Cap issued their Q3 2024 EPS estimates for Cocrystal Pharma in a research report issued to clients and investors on Tuesday, April 23rd. Zacks Small Cap analyst D. Bautz expects that the company will earn ($0.59) per share for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($2.31) per share. Zacks Small Cap also issued estimates for Cocrystal Pharma’s FY2026 earnings at ($2.58) EPS.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last announced its earnings results on Thursday, March 28th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.13.
Read Our Latest Analysis on Cocrystal Pharma
Cocrystal Pharma Trading Up 3.0 %
Shares of COCP opened at $1.56 on Thursday. Cocrystal Pharma has a 12 month low of $1.33 and a 12 month high of $3.29. The firm has a fifty day simple moving average of $1.49 and a 200 day simple moving average of $1.63. The stock has a market capitalization of $15.82 million, a price-to-earnings ratio of -0.78 and a beta of 1.34.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.
Featured Stories
- Five stocks we like better than Cocrystal Pharma
- Pros And Cons Of Monthly Dividend Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- Stock Dividend Cuts Happen Are You Ready?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- How to invest in blue chip stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.